This site is intended for Healthcare Professionals only.

MHRA strengthens restrictions on fluoroquinolone antibiotics


Share post:

Patients are advised to discontinue use of fluoroquinolones at the first signs of a serious adverse reaction

Britain’s drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) on Monday announced that fluoroquinolone antibiotics must only be administered when no other antibiotics are appropriate for use.

It elaborated that fluoroquinolones given systemically (by mouth, injection, or inhalation) should only be prescribed “when other recommended antibiotics have failed, will not work due to resistance, or are unsafe to use in an individual patient.”

Previous regulations on fluoroquinolones stated that this class of antibiotics should not be prescribed for mild to moderate or self-limiting infections, or non-bacterial conditions.

Further restrictions have been introduced after receiving reports from patients who have experienced long-lasting or disabling reactions following use of fluoroquinolones, the MHRA revealed.

Dr Alison Cave, MHRA Chief Safety Officer, said: “Patient safety is our top priority. We have listened to the experience of patients regarding long-lasting and potentially irreversible adverse reactions following use of fluoroquinolone antibiotics, in some cases prescribed for mild-to-moderate infections.

“We recognise fully the importance of limiting the use of these medicines.

“That’s why, from today, fluoroquinolones should only be prescribed when usage of other antibiotics is inappropriate. Fluoroquinolones use should be discontinued at the first signs of a serious adverse reaction,” she added.

Dr Cave encourages patients using fluoroquinolone antibiotics to seek immediate medical help if they experience any adverse reactions.

Serious side effects associated with use of fluoroquinolone antibiotics include tendinitis or tendon rupture, muscle pain, muscle weakness, joint pain, joint swelling, peripheral neuropathy and central nervous system effects.

Patients can report any suspected adverse reactions to fluoroquinolones via the MHRA’s Yellow Card scheme.


Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

RPS releases general election manifesto: Key asks revealed

It urges the next government to review prescription charges in England and strengthen the UK’s medicines supply...

CCA urges urgent action on shortage of designated prescribing practitioners

It has repeatedly warned NHS England of the likely consequences arising from the lack of designated prescribing practitioners  The...

First pharmacist to lead training initiatives for critical care professionals: Reena Mehta

Spearheading the educational efforts and training initiatives for the Intensive Care Society, Reena Mehta ,the first pharmacist, to...

#Fight4Pharmacies: IPA warns ‘there simply won’t be enough community pharmacies left to deliver PFS”

'95 per cent community pharmacies rely on the NHS to sustain,' according to Fight4Pharmacies petition "If the Government does...